The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis - 14/01/12
, Andrew P. Yu, PhD b, James Signorovitch, PhD b, Jipan Xie, MD, PhD b, Magda Tsaneva, BA b, Shiraz R. Gupta, PharmD, MPH c, Yanjun Bao, PhD c, Parvez M. Mulani, PhD c
Correspondence to: Alexa Boer Kimball, MD, MPH, Harvard Medical School, 50 Staniford St, #246, Boston, MA 02114.Abstract |
Background |
Psoriasis significantly impairs work productivity and daily activities.
Objectives |
We sought to examine the effects of adalimumab on psoriasis-related work productivity and activity impairment and associations between the impairment and psoriasis severity in patients with moderate to severe psoriasis.
Methods |
Data were from the first 16 weeks of the Randomized controlled EValuation of adalimumab Every other week dosing in moderate to severe psoriasis TriAL (REVEAL). Outcomes as measured by the Work Productivity and Activity Impairment Questionnaire for Psoriasis (WPAI-Psoriasis) included employment status, total work productivity impairment, and total activity impairment. Logistic regression and analyses of covariance were used to assess the effects of adalimumab and treatment response (≥75% improvement in Psoriasis Area and Severity Index responders) on WPAI-Psoriasis outcomes. Longitudinal generalized estimating equations and Pearson correlation coefficients were used to assess associations between WPAI outcomes and psoriasis severity.
Results |
Greater improvements in total work productivity impairment and total activity impairment were observed with adalimumab treatment versus placebo (15.5 and 11.1 percentage points, respectively; P < .001). Unemployment rate, total work productivity impairment, and total activity impairment were significantly associated with greater baseline psoriasis severity. Changes in WPAI outcomes were significantly correlated with greater psoriasis severity. The Dermatology Life Quality Index had stronger associations with changes in WPAI outcomes compared with clinical severity measures (Psoriasis Area and Severity Index and Physician Global Assessment).
Limitations |
REVEAL only included WPAI data for 16 weeks. Therefore, long-term impact of adalimumab treatment on productivity outcomes could not be assessed. In addition, information on occupational job title or industry was not collected and data were not adjusted for psoriatic arthritis.
Conclusions |
Adalimumab reduced psoriasis-related work productivity and activity impairment in patients with moderate to severe psoriasis.
Le texte complet de cet article est disponible en PDF.Key words : adalimumab, biologic therapy, cost savings, disease severity, psoriasis, work productivity and activity impairment
Abbreviations used : DLQI, PASI, PGA, REVEAL, TAI, TWPI, WPAI, WPAI-Psoriasis, WPAI-SHP
Plan
| Funding for manuscript development was provided by Abbott Laboratories. Medical writing services were provided by Teresa R. Brtva, PhD, and Cathryn M. Carter, MS, of Arbor Communications Inc, Ann Arbor, MI, and were funded by Abbott Laboratories. |
|
| Disclosure: Dr Kimball is an investigator and consultant for Amgen, Centocor, and Abbott Laboratories and has received fellowship grants from Centocor. Drs Yu, Signorovitch, and Xie, and Ms Tsaneva are employees of Analysis Group Inc, which is under contract with Abbott Laboratories. Drs Gupta, Bao, and Mulani are employees of Abbott Laboratories and hold stock in Abbott Laboratories. |
|
| Reprints not available from the authors. |
Vol 66 - N° 2
P. e67-e76 - février 2012 Retour au numéro
Article précédent
- Cutaneous small-vessel vasculitis associated with solid organ malignancies: The Mayo Clinic experience, 1996 to 2009
- Joshua O. Podjasek, David A. Wetter, Mark R. Pittelkow, David A. Wada
- Iotaderma #217
- Robert I. Rudolph
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?